Research and Development

Boehringer Ingelheim and UK biotech firm Oxford BioTherapeutics (OBT) have signed a deal to discover novel antibody targets in cancer. …

The European Medicines Agency (EMA) has been ordered in an interim ruling by the General Court of the European Union …

GlaxoSmithKline has terminated its three-year old agreement with Impax Pharmaceuticals to develop investigational Parkinson’s disease drug IPX066. “The decision has …

Pfizer and Merck have unveiled a major new alliance in diabetes which is likely to raise the stakes in the …

Healthcare marketing agency Evolution Marketing Research has appointed David Hooper to the firm as senior director, Research. Hooper brings more …

The Cancer Treatment Centers of America (CTCA) network has made a change in its executive leadership with the appointment of  …

Merck’s pipeline has been given a boost by an FDA decision to designate early-stage investigational drug lambrolizumab as a breakthrough …

The current model by which pharma carries out R&D is ‘untenable’, according to a new report. But the research, from …

Boehringer Ingelheim has failed to uphold high standards, according to the PMCPA, which enforces the ABPI Code of Practice, over …

Cancer support service company Navigating Cancer has appointed Suzanne Greenwood to the firm as vice president, Bio-Pharmaceutical Services. Greenwood has …

The Institute of Cancer Research (ICR) in London has become the first recipient of money from a £50 million fund …

Roche is to cut around 170 jobs in Europe and the US as part of a restructure of its life …

It was great to be back at SonoPharm, it was so still at this time of day and she went …

Samedan Ltd has extended its range of market-leading pharmaceutical magazines with the acquisition of the Pharmafile portfolio. The London-based firm …

Merck & Co and Bristol-Myers Squibb have signed a non-exclusive agreement to conduct a Phase II trial looking at a …